LATEST
Janel agreed to acquire EnCor BiotechnologynewNightfood Holdings acquired Jun Long Machine IndustrialnewClimb Global Solutions acquired NeoVADnewValor Energy agreed to acquire Glorious StarOakley Capital / Global Loan Agency ServicesTA Associates / MedEnvision: majority stakeLSEG agreed to acquire OctusStord / AMS Fulfillment: investmentCencora agreed to acquire American Oncology NetworkAPEX / KoraiSmith & Wesson Brands agreed to acquire Long Range IntermediateBose acquired Skullcandy
Open App
Agreement signedPublished 30 Sep 2022

Coeptis /
Statera

Coeptis and Statera Discuss Entolimod Asset Purchase

Terms
Not stated
Stage
Agreement signed
Source · 30 Sep 2022
See the source
01 / BuyerCoeptis
02 / TargetStatera
01

What happened

Coeptis and Statera agreed to an exclusivity period while they review a definitive agreement for a potential purchase of assets related to Entolimod and other TLR5 agonists.

The proposed terms include six million USD plus revenue-based milestone payments. Coeptis is continuing its due diligence review.

02

The source

Everything on this page comes from the source below.

01
Source · Source

Coeptis and Statera Discuss Entolimod Asset Purchase

This document is the source for the companies, stage and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.